Search results for "density [charge]"

showing 10 items of 318 documents

Elevated Regulatory T Cell Levels in Glaucoma Patients in Comparison to Healthy Controls.

2016

Many studies analyzing neurodegenerative diseases demonstrate altered frequencies of regulatory T cells (Tregs). Till date, there is hardly any information concerning Tregs in glaucoma. To gather first results concerning Treg levels in glaucoma patients, we aimed to investigate whether the number of CD4(+)CD25(+)T cells vary in the patients suffering from primary open-angle glaucoma (POAG) and healthy controls.Heparinized blood samples were collected from 16 healthy individuals and 16 POAG patients. The groups were age and gender matched. A density gradient centrifugation over Ficoll-Paque was performed to isolate the peripheral blood mononuclear cells. The resulting cells were stained with…

0301 basic medicineMalePathologymedicine.medical_specialtyRegulatory T cellGlaucomaCell SeparationPeripheral blood mononuclear cellT-Lymphocytes RegulatoryFlow cytometry03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundmedicineCentrifugation Density GradientHumansIL-2 receptorLymphocyte CountFluoresceinmedicine.diagnostic_testbiologybusiness.industryInterleukin-2 Receptor alpha SubunitCell sortingMiddle Agedmedicine.diseaseFlow Cytometryeye diseasesSensory SystemsHealthy VolunteersOphthalmology030104 developmental biologymedicine.anatomical_structurechemistryImmunologyCD4 Antigensbiology.proteinFemalebusinessPhycoerythrinGlaucoma Open-AngleCurrent eye research
researchProduct

How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-…

2019

Abstract Background Zoledronic Acid is a bisphosphonate used in a 4-week schedule for the treatment of bone metastases. Some randomized trials supported its role also when administered every 12 weeks. Methods we performed a systematic review and a meta-analysis in order to evaluate the two different schedules in terms of skeletal morbidity rate (SMR), skeletal related events (SRE) and adverse events (AEs). Results our results showed a clinical difference favouring the 12-week schedule in terms of AEs (RR 1.17, 95% CI 1.06–1.29). No signifcant differences were found for SMR (RR 0.97, 95% CI 0.84–1.13) and SRE (RR 1.02, 95% CI 0.89–1.16). Conclusions Our findings support in clinical practice …

0301 basic medicineMalemedicine.medical_specialtyMeta-AnalysiBone Density Conservation Agentmedicine.medical_treatmentBone NeoplasmsBreast NeoplasmsBone NeoplasmZoledronic Acidlaw.invention03 medical and health sciencesProstate cancer0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansHypocalcaemiaBreastAdverse effectBone Density Conservation AgentsSolid tumorbusiness.industryMortality rateProstateProstatic NeoplasmsAEHematologyBisphosphonateSMRmedicine.diseaseBone metastase030104 developmental biologyZoledronic acidTreatment OutcomeOncology030220 oncology & carcinogenesisMeta-analysisProstatic NeoplasmFemalebusinessBreast Neoplasmmedicine.drugHuman
researchProduct

Cortical Reorganization after Rehabilitation in a Patient with Conduction Aphasia Using High-Density EEG

2020

Conduction aphasia is a language disorder occurred after a left-brain injury. It is characterized by fluent speech production, reading, writing and normal comprehension, while speech repetition is impaired. The aim of this study is to investigate the cortical responses, induced by language activities, in a sub-acute stroke patient affected by conduction aphasia before and after an intensive speech therapy training. The patient was examined by using High-Density Electroencephalogram (HD-EEG) examination, while was performing language tasks. the patient was evaluated at baseline and after two months after rehabilitative treatment. Our results showed that an intensive rehabilitative process, i…

0301 basic medicineSpeech productionmedicine.medical_specialtymedicine.medical_treatmentlcsh:Technologyrehabilitationlcsh:Chemistry03 medical and health sciences0302 clinical medicinePhysical medicine and rehabilitationConduction aphasiaNeuroplasticitymedicineGeneral Materials ScienceLanguage disorderInstrumentationStrokelcsh:QH301-705.5Fluid Flow and Transfer ProcessesHigh-Density EEGRehabilitationbusiness.industrylcsh:TProcess Chemistry and TechnologyGeneral Engineeringmedicine.diseaselcsh:QC1-999Computer Science ApplicationsComprehension030104 developmental biologylcsh:Biology (General)lcsh:QD1-999lcsh:TA1-2040Speech repetitionbusinessconduction aphasialcsh:Engineering (General). Civil engineering (General)brain plasticity030217 neurology & neurosurgerylcsh:PhysicsApplied Sciences
researchProduct

Treatment of multiple myeloma-related bone disease

2021

In this Policy Review, the Bone Working Group of the International Myeloma Working Group updates its clinical practice recommendations for the management of multiple myeloma-related bone disease. After assessing the available literature and grading recommendations using the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) method, experts from the working group recommend zoledronic acid as the preferred bone-targeted agent for patients with newly diagnosed multiple myeloma, with or without multiple myeloma-related bone disease. Once patients achieve a very good partial response or better, after receiving monthly zoledronic acid for at least 12 months, the treating…

0301 basic medicinemedicine.medical_specialtyBone Density Conservation AgentBone disease03 medical and health sciences0302 clinical medicineSpinal cord compressionmedicineHumansMultiple myelomaBone Density Conservation Agentsbusiness.industrymedicine.diseaseSurgeryDiscontinuationTransplantationBone Density Conservation Agents030104 developmental biologyZoledronic acidDenosumabOncology030220 oncology & carcinogenesisPractice Guidelines as TopicBone DiseasesbusinessBone DiseaseMultiple Myelomamedicine.drugHumanThe Lancet Oncology
researchProduct

Cost-effectiveness of buffered soluble alendronate 70 mg effervescent tablet for the treatment of postmenopausal women with osteoporosis in Italy

2021

Summary The use of buffered soluble alendronate 70 mg effervescent tablet, a convenient dosing regimen for bisphosphonate therapy, seems a cost-effective strategy compared with relevant alternative treatments for postmenopausal women with osteoporosis aged 60 years and over in Italy. Introduction To assess the cost-effectiveness of buffered soluble alendronate (ALN) 70 mg effervescent tablet compared with relevant alternative treatments for postmenopausal osteoporotic women in Italy. Methods A previously validated Markov microsimulation model was adjusted to the Italian healthcare setting to estimate the lifetime costs (expressed in €2019) per quality-adjusted life-years (QALY) of buffered …

0301 basic medicinemedicine.medical_specialtyeconomic evaluationCost effectivenessCost-Benefit AnalysisEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrology030209 endocrinology & metabolismAlendronate . Buffered soluble alendronate . Cost-effectiveness . Economic evaluation . Effervescent tablets . Osteoporosis . TreatmentAlendronate; Buffered soluble alendronate; Cost-effectiveness; Economic evaluation; Effervescent tablets; Osteoporosis; Treatment; Aged; Alendronate; Cost-Benefit Analysis; Female; Humans; Italy; Middle Aged; Observational Studies as Topic; Postmenopause; Quality-Adjusted Life Years; Tablets; Bone Density Conservation Agents; Osteoporosis; Osteoporosis Postmenopausal03 medical and health sciences0302 clinical medicinemedicineHumansEffervescent tabletOsteoporosis PostmenopausalAgedBone mineralPostmenopausal womenBone Density Conservation AgentstreatmentAlendronatebusiness.industrybuffered soluble alendronateMiddle AgedBisphosphonatemedicine.diseaseosteoporosisPostmenopauseObservational Studies as TopicDenosumabZoledronic acidItalyeffervescent tabletsPostmenopausalFemaleOriginal ArticleCost-effectivenessQuality-Adjusted Life Years030101 anatomy & morphologybusinessTabletsmedicine.drugOsteoporosis International
researchProduct

Spatial analysis of traffic accidents near and between road intersections in a directed linear network.

2019

Although most of the literature on traffic safety analysis has been developed over areal zones, there is a growing interest in using the specific road structure of the region under investigation, which is known as a linear network in the field of spatial statistics. The use of linear networks entails several technical complications, ranging from the accurate location of traffic accidents to the definition of covariates at a spatial micro-level. Therefore, the primary goal of this study was to display a detailed analysis of a dataset of traffic accidents recorded in Valencia (Spain), which were located into a linear network representing more than 30 km of urban road structure corresponding t…

050210 logistics & transportationModels StatisticalComputer science05 social sciencesKernel density estimationPublic Health Environmental and Occupational HealthNegative binomial distributionAccidents TrafficHuman Factors and ErgonomicsRangingSpatial heterogeneityLinear networkSpatio-Temporal AnalysisOverdispersionSpain0502 economics and businessStatisticsCovariateHumans0501 psychology and cognitive sciencesBuilt EnvironmentSafety Risk Reliability and QualitySpatial analysis050107 human factorsAccident; analysis and prevention
researchProduct

Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients.

2009

BACKGROUND: Bisphosphonate-associated osteonecrosis of the jaws (BP-ONJ) is a relatively new disease. The aim of this study was to evaluate the prevalence of BP-ONJ in breast cancer patients with osseous metastasis and bisphosphonate therapy. METHODS: A retrospective study was conducted in a EUSOMA accredited breast unit in Germany. All patients treated from January of 2000 to March of 2006 with metastatic breast cancer and bisphosphonate therapy were reviewed. All patients were contacted, and missing data were completed through structured interviews with their dentists and physicians (n = 75). Primary outcome was the development of BP-ONJ and the detection of possible additional trigger fa…

AdultCancer Researchmedicine.medical_specialtymedicine.medical_treatmentOral Surgical ProceduresBone NeoplasmsBreast NeoplasmsBreast cancerInternal medicineMedicineHumansAgedRetrospective StudiesAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryIncidence (epidemiology)IncidenceOsteonecrosisBone metastasisCancerRetrospective cohort studyBisphosphonateMiddle Agedmedicine.diseasePrognosisMetastatic breast cancerSurgeryOncologyBreast diseasebusinessJaw DiseasesCancer
researchProduct

Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis.

2006

Background:  Patients treated with bisphosphonates because of bone metastases have been shown to develop osteonecrosis of the jaws. In the present study, we examined the histologic findings of these cases. As similarities between this disorder and infected osteoradionecrosis (IORN) are described, both lesions were compared. Methods:  We investigated eight patients with bisphosphonate treatment and osteonecrosis (four female, four male; median age: 65.6 years; cancer: multiple myeloma in five patients, breast cancer in three patients; mandibular involvement in five patients, maxillar involvement in three cases), and 10 patients suffering from IORN (all male; median age: 61.3 years; cancer: s…

AdultMaleCancer ResearchPathologymedicine.medical_specialtyOsteoradionecrosisAdenoid cystic carcinomamedicine.medical_treatmentAntineoplastic AgentsBone NeoplasmsBone resorptionPathology and Forensic MedicineBreast cancermedicineCarcinomaActinomycesHumansMultiple myelomaAgedAged 80 and overBone Density Conservation AgentsDiphosphonatesbusiness.industryOsteonecrosisCancerBisphosphonateMiddle Agedmedicine.diseaseCarcinoma Adenoid CysticOtorhinolaryngologyOsteoradionecrosisCarcinoma Squamous CellPeriodonticsFemaleOral SurgerybusinessJaw DiseasesJournal of oral pathologymedicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
researchProduct

Surgery-triggered and non surgery-triggered Bisphosphonate-related Osteonecrosis of the Jaws (BRONJ): A retrospective analysis of 567 cases in an Ita…

2011

Invasive local procedures are often reported in clinical history of patients suffering from Bisphosphonates-Related Osteonecrosis of the Jaws (BRONJ) but over 40% of spontaneous forms have been also described in literature. We compared age, gender, underlying bone disorders, bisphosphonate therapy, clinical features and surgical outcome of 205 cases (36.2%) of BRONJ non surgery-triggered (group 1) with 362 (63.8%) cases of surgery-triggered forms (group 2). Differences between group 1 and 2 were analysed using Mann-Whitney U and χ2 tests. Statistical analysis was performed using STATA 8. Zoledronate was the most used type of bisphosphonate (63.4% versus 69.0%) and the mandible was the most …

AdultMaleCancer Researchmedicine.medical_specialtyTooth extractionmedicine.medical_treatmentZoledronic AcidSettore MED/28 - Malattie OdontostomatologicheRisk FactorsClinical historySpontaneous formmedicineRetrospective analysisHumansStatistical analysisStage (cooking)AgedRetrospective StudiesAged 80 and overSurgical outcomeBone Density Conservation AgentsDiphosphonatesBRONJOrthognathic Surgical Proceduresbusiness.industryImidazolesOsteonecrosisBisphosphonates-related Osteonecrosis of the JawMiddle AgedBisphosphonateSurgeryZoledronic acidItalyOncologyMulticenter studyFemaleBisphosphonate therapyOral SurgerybusinessJaw Diseasesmedicine.drugOral Oncology
researchProduct

Staging of osteonecrosis of the jaw requires computed tomography for accurate definition of the extent of bony disease

2014

AbstractManagement of osteonecrosis of the jaw associated with antiresorptive agents is challenging, and outcomes are unpredictable. The severity of disease is the main guide to management, and can help to predict prognosis. Most available staging systems for osteonecrosis, including the widely-used American Association of Oral and Maxillofacial Surgeons (AAOMS) system, classify severity on the basis of clinical and radiographic findings. However, clinical inspection and radiography are limited in their ability to identify the extent of necrotic bone disease compared with computed tomography (CT). We have organised a large multicentre retrospective study (known as MISSION) to investigate th…

AdultMaleCutaneous FistulaSettore MED/50 - Scienze Tecniche Mediche ApplicateDental Fistulastaging system; bisphosphonate; computed tomography; aaoms; osteonecrosis of the jaw; antiresorptive agentsAAOMSAntiresorptive agentSettore MED/29 - Chirurgia MaxillofaccialeAAOMS Antiresorptive agents Bisphosphonate Computed tomography Osteonecrosis of the jaw Staging systemBronj; AAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemSettore MED/28 - Malattie OdontostomatologicheMandibular FracturesBronjOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAlveolar ProcessHumansBisphosphonateMandibular DiseasesComputed tomographyAgedRetrospective StudiesAged 80 and overSuppurationBone Density Conservation AgentsOsteonecrosis of the jawPatient AcuityAntiresorptive agentsCone-Beam Computed TomographyMiddle AgedStaging systemMaxillary DiseasesPhenotypeOtorhinolaryngologyTooth ExtractionBisphosphonate-Associated Osteonecrosis of the JawDrug Therapy CombinationFemaleSurgeryOsteonecrosis of the jaw; Bisphosphonate; Staging system; AAOMS; Computed tomography; Antiresorptive agentsAAOMS; Antiresorptive agents; Bisphosphonate; Computed tomography; Osteonecrosis of the jaw; Staging systemOral SurgeryTomography X-Ray ComputedTomography Spiral ComputedOsteosclerosis
researchProduct